Industry leaders launch Actionable Genome Consortium
November 2014
by  |  Email the author

SHARING OPTIONS:

SAN DIEGO—Illumina Inc. and four leading cancer centers have established the Actionable Genome Consortium (AGC), an initiative that will recommend openly published standards for widespread use of next-generation sequencing to aid in treatment decision for cancer patients. Specifically, the AGC will aim to define the principles and content of the “cancer actionable genome,” a comprehensive description of genomic alterations that define individuals’ tumors. The founding members include, other than Illumina, the Dana-Farber Cancer Institute, Fred Hutchinson Cancer Research Center, MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center. The AGC will publish a list of actionable events—including best practices regarding biopsy samples, performance standards for sequencing, guidelines for clinical reports and standards for genetic variants—and include a research arm for collaborative, cross-institutional projects regarding leading challenges in molecular oncology.
Code:

Back
 
CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.